2.4.0.84140 - Disclosure - Acquisitions, License and Research Agreements (Details)truefalseIn Millions, unless otherwise specifiedfalse1false USDtruefalseD2011Q4_M11_DuoCortPharmaAbMemberhttp://www.sec.gov/CIK0000946840duration2011-11-01T00:00:002011-11-30T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberItemStandardhttp://www.viropharma.com/20130630itemvphm0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$2false SEKtruefalseD2011Q4_M11_DuoCortPharmaAbMemberhttp://www.sec.gov/CIK0000946840duration2011-11-01T00:00:002011-11-30T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberItemStandardhttp://www.viropharma.com/20130630itemvphm0SEKStandardhttp://www.xbrl.org/2003/iso4217SEKiso421703false USDtruefalse$I2011Q4_M1130_DuoCortPharmaAbMember_ContingentPaymentsRelateToCertainMilestonesMember_MaximumMemberhttp://www.sec.gov/CIK0000946840instant2011-11-30T00:00:000001-01-01T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseMilestonesus-gaap_ContingentConsiderationByTypeAxisxbrldihttp://xbrl.org/2006/xbrldivphm_ContingentPaymentsRelateToCertainMilestonesMemberus-gaap_ContingentConsiderationByTypeAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false SEKtruefalseI2011Q4_M1130_DuoCortPharmaAbMember_ContingentPaymentsRelateToCertainMilestonesMember_MaximumMemberhttp://www.sec.gov/CIK0000946840instant2011-11-30T00:00:000001-01-01T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseMilestonesus-gaap_ContingentConsiderationByTypeAxisxbrldihttp://xbrl.org/2006/xbrldivphm_ContingentPaymentsRelateToCertainMilestonesMemberus-gaap_ContingentConsiderationByTypeAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberSEKStandardhttp://www.xbrl.org/2003/iso4217SEKiso42170SEKSEK5false USDtruefalse$I2011Q4_M1130_DuoCortPharmaAbMember_ContingentPaymentsRelateToCertainMilestonesMember_MinimumMemberhttp://www.sec.gov/CIK0000946840instant2011-11-30T00:00:000001-01-01T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseMilestonesus-gaap_ContingentConsiderationByTypeAxisxbrldihttp://xbrl.org/2006/xbrldivphm_ContingentPaymentsRelateToCertainMilestonesMemberus-gaap_ContingentConsiderationByTypeAxisexplicitMemberfalsefalseMinimumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false SEKtruefalseI2011Q4_M1130_DuoCortPharmaAbMember_ContingentPaymentsRelateToCertainMilestonesMember_MinimumMemberhttp://www.sec.gov/CIK0000946840instant2011-11-30T00:00:000001-01-01T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseMilestonesus-gaap_ContingentConsiderationByTypeAxisxbrldihttp://xbrl.org/2006/xbrldivphm_ContingentPaymentsRelateToCertainMilestonesMemberus-gaap_ContingentConsiderationByTypeAxisexplicitMemberfalsefalseMinimumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMemberSEKStandardhttp://www.xbrl.org/2003/iso4217SEKiso42170SEKSEK7false USDtruefalse$I2011Q4_M1130_DuoCortPharmaAbMember_ContingentPaymentsRelateToSpecificRegulatoryMilestonesMember_MaximumMemberhttp://www.sec.gov/CIK0000946840instant2011-11-30T00:00:000001-01-01T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseSpecific Regulatory Milestonesus-gaap_ContingentConsiderationByTypeAxisxbrldihttp://xbrl.org/2006/xbrldivphm_ContingentPaymentsRelateToSpecificRegulatoryMilestonesMemberus-gaap_ContingentConsiderationByTypeAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false SEKtruefalseI2011Q4_M1130_DuoCortPharmaAbMember_ContingentPaymentsRelateToSpecificRegulatoryMilestonesMember_MaximumMemberhttp://www.sec.gov/CIK0000946840instant2011-11-30T00:00:000001-01-01T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseSpecific Regulatory Milestonesus-gaap_ContingentConsiderationByTypeAxisxbrldihttp://xbrl.org/2006/xbrldivphm_ContingentPaymentsRelateToSpecificRegulatoryMilestonesMemberus-gaap_ContingentConsiderationByTypeAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberSEKStandardhttp://www.xbrl.org/2003/iso4217SEKiso42170SEKSEK9false USDtruefalse$I2011Q4_M1130_DuoCortPharmaAbMember_ContingentPaymentsRelateToCommercialMilestonesMember_MaximumMemberhttp://www.sec.gov/CIK0000946840instant2011-11-30T00:00:000001-01-01T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseCommercial Milestonesus-gaap_ContingentConsiderationByTypeAxisxbrldihttp://xbrl.org/2006/xbrldivphm_ContingentPaymentsRelateToCommercialMilestonesMemberus-gaap_ContingentConsiderationByTypeAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10false SEKtruefalseI2011Q4_M1130_DuoCortPharmaAbMember_ContingentPaymentsRelateToCommercialMilestonesMember_MaximumMemberhttp://www.sec.gov/CIK0000946840instant2011-11-30T00:00:000001-01-01T00:00:00falsefalseDuoCort Pharma ABus-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivphm_DuoCortPharmaAbMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseCommercial Milestonesus-gaap_ContingentConsiderationByTypeAxisxbrldihttp://xbrl.org/2006/xbrldivphm_ContingentPaymentsRelateToCommercialMilestonesMemberus-gaap_ContingentConsiderationByTypeAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberSEKStandardhttp://www.xbrl.org/2003/iso4217SEKiso42170SEKSEK1true 3us-gaap_BusinessAcquisitionLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Business acquisition2false 4us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquiredus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truetruefalse1.001.00falsefalsefalse2truetruefalse1.001.00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10falsetruefalse00falsefalsefalsenum:percentItemTypepurePercentage of voting equity interests acquired in the business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 68 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Ownership interest (as a percent)3false 4us-gaap_BusinessAcquisitionCostOfAcquiredEntityCashPaidus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3210000032.1USD$falsetruefalse2truefalsefalse213000000213.0SEKfalsetruefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash paid to acquire the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 68 -Subparagraph f(1) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Upfront cash payment of acquisition4false 4us-gaap_BusinessAcquisitionContingentConsiderationPotentialCashPaymentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse128000000128falsefalsefalse4truefalsefalse860000000860falsefalsefalse5truefalsefalse3600000036falsefalsefalse6truefalsefalse240000000240falsefalsefalse7truefalsefalse2400000024falsefalsefalse8truefalsefalse160000000160falsefalsefalse9truefalsefalse104000000104falsefalsefalse10truefalsefalse700000000700falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of potential cash payments that could result from the contingent consideration arrangement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph f -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Contingent consideration, potential cash payment5false 4vphm_NumberOfComponentsOfContingentConsiderationPaymentsvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse33falsefalsefalse2truefalsefalse33falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerThe number of components of contingent consideration payments.No definition available.false256Number of components of contingent consideration payments6false 4us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCostsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse14000001.4USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 24 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Transaction costs incurred on acquisitionfalseAcquisitions, License and Research Agreements (Details) (DuoCort Pharma AB)HundredThousandsUnKnownUnKnownUnKnowntruefalsetrueSheethttp://www.viropharma.com/role/DisclosureAcquisitionsLicenseAndResearchAgreementsDetails106